Loading organizations...
Based in Seattle, Washington, DexCare provides a healthcare platform-as-a-service that intelligently orchestrates health system capacity and digital patient demand across multiple lines of care. The enterprise software integrates directly with existing clinical infrastructure to navigate patients to appropriate care settings while simultaneously balancing provider supply to reduce operational bottlenecks. Operating under a venture-backed business model, the organization has raised $110 million in total funding to scale its access optimization technology nationwide. The platform demonstrated significant scalability by managing a 30-fold increase in patient visit volume during the pandemic, leading to adoption by prominent healthcare networks and strategic investors such as Providence, Kaiser Permanente, Mass General Brigham, and Texas Health Resources. Originally incubated within the Providence health system in 2016, the business was officially spun out as an independent corporate entity in 2021 by founder Derek Streat.
DexCare has raised $145.0M across 3 funding rounds.
DexCare has raised $145.0M in total across 3 funding rounds.
DexCare has raised $145.0M across 3 funding rounds. Most recently, it raised $75.0M Series C in June 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2023 | $75M Series C | Caroline XIE | AlleyCorp, Andreessen Horowitz, B Capital Group, Curie.bio, Define Ventures, Dragoneer Investment Group, General Catalyst, Mubadala, Operator Partners, Thirty Five Ventures, Transformation Capital, UP.Partners, Ayman Alabdallah, Frist Cressey Ventures, Kaiser Permanente Ventures, Springrock Ventures | Announced |
| Jan 1, 2022 | $50M Series B | Transformation Capital | 5AM Ventures, AlleyCorp, Andreessen Horowitz, B Capital Group, Canaan Partners, Curie.bio, Define Ventures, Dragoneer Investment Group, General Catalyst, Kaiser Permanente Ventures, Mubadala, Operator Partners, Thirty Five Ventures, UP.Partners, Ayman Alabdallah, Aaron Martin, Frist Cressey Ventures, LIZ Rockett, Gaye BOK, Sara Vaezy, Springrock Ventures | Announced |
| Mar 1, 2021 | $20M Series A | Define Ventures | Dragoneer Investment Group, Mubadala, Ayman Alabdallah | Announced |
DexCare is a healthcare technology company that builds a real‑time care‑orchestration platform to improve patient access, scheduling, and capacity management for health systems, having spun out of Providence and scaled commercially with enterprise customers and investor backing.[1][2]
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
If you’d like, I can turn this into a one‑page investor memo, extract KPI data from cited case studies, or map DexCare’s competitors and potential acquisition/partnership targets.
DexCare has raised $145.0M in total across 3 funding rounds.
DexCare's investors include Caroline Xie, AlleyCorp, Andreessen Horowitz, B Capital Group, Curie.Bio, Define Ventures, Dragoneer Investment Group, General Catalyst, Mubadala, Operator Partners, Thirty Five Ventures, Transformation Capital.